|

Tuspetinib Clinical Trials

1 actively recruiting trial across 1 location

Also known as: HM43239

Pipeline

Phase 1/2: 1

Top Sponsors

  • Aptose Biosciences Inc.1

Indications

  • Myelodysplastic Syndrome With Excess Blasts-21
  • Relapsed Adult AML1
  • Chronic Myelomonocytic Leukemia1
  • Leukemia, Myeloid, Acute1
  • Refractory AML1

Birmingham, Alabama1 trial

Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia

The Kirklin Clinic of UAB Hospital

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.